Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Reicherts, Christian  [Clear All Filters]
2018
Groth C, van Groningen LFJ, Matos TR, Bremmers ME, Preijers FWMB, Dolstra H, Reicherts C, Schaap NPM, van Hooren EHG, IntHout J, et al. Phase I/II trial of a combination of anti-CD3/CD7 immunotoxins for steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2018.
2021
Roll W, Evers G, Strotmann R, Albring J, Reicherts C, Noto B, Weckesser M, Lenz G, Schäfers M, Stelljes M. F-FDG-PET for the assessment of acute intestinal GvHD and prediction of response to immunosuppressive therapy. Transplant Cell Ther. 2021.
2023
Pohlmann A, Bentgens E, Schülke C, Kuron D, Reicherts C, Marx J, Angenendt L, Mikesch J-H, Lenz G, Stelljes M, et al. Pretransplant spleen volume and outcome after hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML). Ann Hematol. 2023.
2024
Berning P, Kolloch L, Reicherts C, Call S, Marx J, Floeth M, Esseling E, Ronnacker J, Albring J, Schliemann C, et al. Comparable outcomes for TBI-based versus treosulfan based conditioning prior to allogeneic hematopoietic stem cell transplantation in AML and MDS patients. Bone Marrow Transplant. 2024.
Stelljes M, Middeke JMoritz, Bug G, Wagner-Drouet E-M, Müller LP, Schmid C, Krause SW, Bethge W, Jost E, Platzbecker U, et al. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial. Lancet Haematol. 2024.